Restriction of indication for Trivastal Retard (piribedil) to treatment of Parkinson's Disease only

Servier would like to inform healthcare professionals that the indication of Trivastal Retard (piribedil) is now restricted to the treatment of Parkinson's disease, following the benefit-risk assessment of piribedil by the French Agency (ANSM) which was initiated based on pharmacovigilance data. The therapeutic benefit of piribedil was considered positive for Parkinson's disease but insufficiently established for the other registered indications. Healthcare professionals are advised to take into consideration the restricted indication of Trivastal Retard in the clinical management of their patients. Please refer to the letter for more details.  
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.